Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02807844
Title Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals


endometrial carcinoma

pancreatic carcinoma

triple-receptor negative breast cancer


MCS110 + Spartalizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.